Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Imidazo[1,2-a]pyridine-8-carbonitrile is a heterocyclic chemical compound characterized by a molecular formula of C9H5N3. It features an imidazole and pyridine ring system, with a carbonitrile functional group attached at the 8th position. This unique structure endows it with versatile reactivity and potential biological activity, making it a valuable building block for the development of new drugs and bioactive compounds. Additionally, it serves as a research reagent in organic chemistry laboratories for various synthetic purposes.

136117-70-9 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 136117-70-9 Structure
  • Basic information

    1. Product Name: IMidazo[1,2-a]pyridine-8-carbonitrile
    2. Synonyms: IMidazo[1,2-a]pyridine-8-carbonitrile
    3. CAS NO:136117-70-9
    4. Molecular Formula: C8H5N3
    5. Molecular Weight: 143.1454
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 136117-70-9.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: 1.22±0.1 g/cm3(Predicted)
    6. Refractive Index: N/A
    7. Storage Temp.: 2-8°C
    8. Solubility: N/A
    9. PKA: 2.56±0.50(Predicted)
    10. CAS DataBase Reference: IMidazo[1,2-a]pyridine-8-carbonitrile(CAS DataBase Reference)
    11. NIST Chemistry Reference: IMidazo[1,2-a]pyridine-8-carbonitrile(136117-70-9)
    12. EPA Substance Registry System: IMidazo[1,2-a]pyridine-8-carbonitrile(136117-70-9)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 136117-70-9(Hazardous Substances Data)

136117-70-9 Usage

Uses

Used in Pharmaceutical Synthesis:
Imidazo[1,2-a]pyridine-8-carbonitrile is utilized as a key intermediate in the synthesis of pharmaceuticals for its versatile reactivity and potential biological activity. Its unique structure allows for the development of new drugs and bioactive compounds, contributing to the advancement of medicinal chemistry.
Used in Agrochemical Synthesis:
In the agrochemical industry, Imidazo[1,2-a]pyridine-8-carbonitrile is employed as a building block in the creation of new agrochemicals. Its reactivity and potential biological activity make it a valuable component in the development of innovative and effective products for agricultural applications.
Used as a Research Reagent in Organic Chemistry:
Imidazo[1,2-a]pyridine-8-carbonitrile serves as a research reagent in organic chemistry laboratories. Its unique structure and reactivity make it a valuable tool for various synthetic purposes, aiding in the exploration and understanding of chemical reactions and the development of novel synthetic methodologies.

Check Digit Verification of cas no

The CAS Registry Mumber 136117-70-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,6,1,1 and 7 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 136117-70:
(8*1)+(7*3)+(6*6)+(5*1)+(4*1)+(3*7)+(2*7)+(1*0)=109
109 % 10 = 9
So 136117-70-9 is a valid CAS Registry Number.

136117-70-9SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name Imidazo[1,2-a]pyridine-8-carbonitrile

1.2 Other means of identification

Product number -
Other names 8-imidazo<1,2-a>pyridinecarbonitrile

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:136117-70-9 SDS

136117-70-9Relevant articles and documents

Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition

Reich, Siegfried H.,Sprengeler, Paul A.,Chiang, Gary G.,Appleman, James R.,Chen, Joan,Clarine, Jeff,Eam, Boreth,Ernst, Justin T.,Han, Qing,Goel, Vikas K.,Han, Edward Z. R.,Huang, Vera,Hung, Ivy N. J.,Jemison, Adrianna,Jessen, Katti A.,Molter, Jolene,Murphy, Douglas,Neal, Melissa,Parker, Gregory S.,Shaghafi, Michael,Sperry, Samuel,Staunton, Jocelyn,Stumpf, Craig R.,Thompson, Peggy A.,Tran, Chinh,Webber, Stephen E.,Wegerski, Christopher J.,Zheng, Hong,Webster, Kevin R.

, p. 3516 - 3540 (2018/05/01)

Dysregulated translation of mRNA plays a major role in tumorigenesis. Mitogen-activated protein kinase interacting kinases (MNK)1/2 are key regulators of mRNA translation integrating signals from oncogenic and immune signaling pathways through phosphoryla

INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR

-

Page/Page column 90, (2014/02/15)

Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.

4,6-DIAMINONICOTINAMIDE COMPOUND

-

Page/Page column 43, (2011/09/20)

[Problem] The present invention provides a 4,6-diaminonicotinamide compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for treating diseases caused by undesirable and/or abnormal cytokine signal transduction. [Means for Solution] The present inventors have extensively studied compounds having a JAK3 inhibitory action, and as a result, they have found that a 4,6-diaminonicotinamide compound which is the compound of the present invention has an excellent JAK3 inhibitory action and is useful as an agent for preventing or treating diseases caused by undesirable and/or abnormal cytokine signal transduction, thereby completing the present invention.

PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN

-

Page/Page column 41-42, (2012/01/13)

Disclosed are compounds, compositions and methods for treating pain, including inflammatory, visceral, and acute pain. Such compounds are represented by Formula (I) as follows: wherein A1, L1, D, and Q are defined herein.

Prokineticin 1 receptor antagonists

-

Page/Page column 42, (2008/12/04)

The present invention relates to certain novel compounds of Formula (I): and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.

PROKINETICIN 2 RECEPTOR ANTAGONISTS

-

Page/Page column 113, (2010/11/28)

The present invention relates to certain novel compounds of Formula (I): and methods for the treatment of prokineticin 2 or prokinetin 2 receptor mediated disorders.

Imidazo[1,2-a]pyridines. Synthesis and inotropic activity of new 5-imidazo[1,2-a]pyridinyl-2(1H)-pyridinone derivatives

Yamanaka,Miyake,Suda,Ohhara,Ogawa

, p. 1556 - 1567 (2007/10/02)

A series of 1,2-dihydro-5-imidazo[1,2-a]pyridinyl-2(1H)-pyridinones was synthesized and evaluated for positive inotropic activity. 1,2-Dihydro-5-imidazo[1,2-a]pyridin-6-yl-6-methyl-2-oxo-3- pyridinecarbonitrile (11a) hydrochloride monohydrate (E-1020) was found to be a potent and selective inhibitor of phosphodiesterase III and a long-acting, potent, orally active positive inotropic agent. Additional imidazo[1,2-a]pyridin-2-yl (3a), -3-yl (16), -7-yl (20) and -8-yl (24a) compounds were also prepared. Altering the pyridine substitution from the 2-position to the 6-position produced a 2-fold increase in the i.v. cardiotonic potency (ED50) from 52 to 23 μg/kg, while substitution at the 3-, 7- or 8-position reduced potency. In the 2-positional isomers, introduction of halogen groups enhanced the activity and 3-chloro-1,2-dihydro-5-(6-fluoroimidazo[1,2-a]pyridin-2-yl)-6-methyl-2(1H)- pyridinone (3a) was the most potent (i.v. ED50 11 μg/kg) in this seris. E-1020 is presently under development for the treatment of congestive heart failure.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 136117-70-9